Cellectis (NASDAQ:CLLS) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS) in a report published on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays dropped their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Trading Down 1.6 %

Shares of Cellectis stock opened at $1.83 on Thursday. Cellectis has a 1 year low of $1.70 and a 1 year high of $3.77. The company’s fifty day simple moving average is $1.98 and its 200-day simple moving average is $2.22. The company has a market cap of $101.72 million, a price-to-earnings ratio of -1.44 and a beta of 3.10. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same quarter in the prior year, the business earned ($0.31) earnings per share. As a group, sell-side analysts expect that Cellectis will post -0.46 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CLLS. XTX Topco Ltd acquired a new stake in shares of Cellectis in the 2nd quarter valued at $29,000. First Affirmative Financial Network acquired a new position in Cellectis in the third quarter valued at about $45,000. Principal Financial Group Inc. grew its stake in Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after buying an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC grew its stake in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after buying an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.